Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Regeneron Pharmaceuticals
(NQ:
REGN
)
1,031.15
-14.83 (-1.42%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,002,801
Open
1,048.52
Bid (Size)
1,051.00 (1)
Ask (Size)
1,097.00 (1)
Prev. Close
1,045.98
Today's Range
1,008.41 - 1,048.52
52wk Range
769.19 - 1,211.20
Shares Outstanding
91,779,465
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
A Closer Look at Regeneron Pharmaceuticals's Options Market Dynamics
Today 11:45 EDT
Via
Benzinga
Exploring The Competitive Space: Regeneron Pharmaceuticals Versus Industry Peers In Biotechnology
Today 11:00 EDT
Via
Benzinga
Performance
YTD
+13.94%
+13.94%
1 Month
-14.03%
-14.03%
3 Month
-3.74%
-3.74%
6 Month
+7.02%
+7.02%
1 Year
+23.54%
+23.54%
More News
Read More
Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market
Today 8:04 EDT
Via
Benzinga
Why Is Regeneron Pharmaceuticals Stock Trading Lower On Tuesday?
September 24, 2024
Via
Benzinga
This BP Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
September 24, 2024
Via
Benzinga
Tesla Leads S&P 500 Index, While Biotech Giant Tumbles On Court Ruling
September 23, 2024
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
Smart Money Is Betting Big In REGN Options
September 23, 2024
Via
Benzinga
Competitor Analysis: Evaluating Regeneron Pharmaceuticals And Competitors In Biotechnology Industry
September 11, 2024
Via
Benzinga
Regeneron Dives As Amgen Tees Up Its Rival To Moneymaking Machine Eylea
September 23, 2024
Via
Investor's Business Daily
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old
September 20, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
September 13, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Time To Invest And Or Trade In Bio-Tech Stocks?
September 13, 2024
Via
Talk Markets
Topics
ETFs
$1000 Invested In This Stock 5 Years Ago Would Be Worth $4,000 Today
September 10, 2024
Via
Benzinga
Beyond The Numbers: 20 Analysts Discuss Regeneron Pharmaceuticals Stock
September 09, 2024
Via
Benzinga
Biotech Breakout: Stocks for Your Watchlist
September 12, 2024
Via
MarketBeat
Topics
ETFs
Sanofi, Regeneron Drug Dupixent Shows Successful Treatment Of Patients With Inflammatory Skin Disease
September 11, 2024
Via
Benzinga
MAIA Biotechnology's Phase 2 Study Of THIO In Non-Small Cell Lung Cancer Shows Positive Interim Survival Benefits
September 11, 2024
Via
News Direct
EYLEA HD® (aflibercept) Injection 8 mg Data at EURETINA Reinforce Long-term Durability, Sustained Fluid Control and Safety Profile
September 11, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Prediction: These 2 Companies Will Split Their Stocks by 2027
September 11, 2024
Via
The Motley Fool
Dupixent® (dupilumab) Phase 3 Trial Confirms Significant Improvements in Itch and Hives for Patients with Chronic Spontaneous Urticaria (CSU)
September 11, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Dupixent® (dupilumab) Is the First and Only Biologic to Achieve Significant Improvements in Disease Remission and Symptoms in Bullous Pemphigoid (BP) Positive Pivotal Trial
September 11, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Libtayo® (cemiplimab) Demonstrates Durable Survival Benefit at Five Years in Advanced Non-small Cell Lung Cancer
September 09, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Regeneron to Highlight Progress Across Its Differentiated Oncology Portfolio and Pipeline at WCLC and ESMO
September 09, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Prediction: These 2 Cathie Wood Stocks Could Crush the Market Through 2030
September 05, 2024
Via
The Motley Fool
Biotech And Life Science Sector Update Summer Of 2024
August 29, 2024
Via
Talk Markets
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.